Compass Therapeutics announced that its abstract on tovecimig has been accepted for an oral Proffered Paper presentation at the European Society for Medical Oncology Congress 2026. The presentation will highlight results from the randomized, controlled Phase 2/3 COMPANION-002 clinical trial evaluating tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel in patients with advanced biliary tract cancer. The trial data will be presented by Dr. Nilofer Azad of Johns Hopkins University on Saturday, October 24, 2026, during a session from 10:15am to 11:45am CET. The ESMO Congress will take place October 23-27, 2026 in Madrid, Spain.
Compass Therapeutics Inc.Abstract on tovecimig accepted for oral presentation at ESMO Congress 2026, highlighting positive Phase 2/3 trial results.